Cargando…
Immunological recovery in patients with pulmonary tuberculosis after intensive phase treatment
OBJECTIVES: This study aimed to examine the change and significance of immune parameters in patients with sputum smear-positive pulmonary tuberculosis (TB) after 2 months of intensive phase anti-TB treatment. METHODS: The immune parameters of 232 cases of sputum smear-positive pulmonary TB were dete...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6136029/ https://www.ncbi.nlm.nih.gov/pubmed/29756540 http://dx.doi.org/10.1177/0300060518773258 |
_version_ | 1783354928910041088 |
---|---|
author | Luo, Xuejiao Wu, Furong Ma, Jun Xiao, Heping Cui, Haiyan |
author_facet | Luo, Xuejiao Wu, Furong Ma, Jun Xiao, Heping Cui, Haiyan |
author_sort | Luo, Xuejiao |
collection | PubMed |
description | OBJECTIVES: This study aimed to examine the change and significance of immune parameters in patients with sputum smear-positive pulmonary tuberculosis (TB) after 2 months of intensive phase anti-TB treatment. METHODS: The immune parameters of 232 cases of sputum smear-positive pulmonary TB were detected before and after 2 months of intensive phase anti-TB treatment and compared with 50 cases from healthy volunteers (controls). The T lymphocyte cell population in peripheral blood was detected using flow cytometry. Serum levels of interleukin (IL)-1β, soluble interleukin-2 receptor, IL-6, and tumour necrosis factor-α were measured by ELISA. RESULTS: After 2 months of intensive phase anti-TB treatment, a reduction in the percentage of CD4+ T cells showed a significant restoration similar to that of controls. Moreover, after intensive anti-TB treatment, serum levels of IL-1β, soluble interleukin-2 receptor, IL-6, and tumour necrosis factor-α were significantly decreased compared with before treatment. Additionally, serum levels of IL-1β and IL-6 showed a diminished recovery compared with controls. CONCLUSIONS: Our findings suggest immunological recovery in patients with pulmonary TB after intensive phase treatment. Therefore, serum cytokine levels are considered potential host biomarkers for monitoring the response of treatment for pulmonary TB. |
format | Online Article Text |
id | pubmed-6136029 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-61360292018-09-17 Immunological recovery in patients with pulmonary tuberculosis after intensive phase treatment Luo, Xuejiao Wu, Furong Ma, Jun Xiao, Heping Cui, Haiyan J Int Med Res Clinical Research Reports OBJECTIVES: This study aimed to examine the change and significance of immune parameters in patients with sputum smear-positive pulmonary tuberculosis (TB) after 2 months of intensive phase anti-TB treatment. METHODS: The immune parameters of 232 cases of sputum smear-positive pulmonary TB were detected before and after 2 months of intensive phase anti-TB treatment and compared with 50 cases from healthy volunteers (controls). The T lymphocyte cell population in peripheral blood was detected using flow cytometry. Serum levels of interleukin (IL)-1β, soluble interleukin-2 receptor, IL-6, and tumour necrosis factor-α were measured by ELISA. RESULTS: After 2 months of intensive phase anti-TB treatment, a reduction in the percentage of CD4+ T cells showed a significant restoration similar to that of controls. Moreover, after intensive anti-TB treatment, serum levels of IL-1β, soluble interleukin-2 receptor, IL-6, and tumour necrosis factor-α were significantly decreased compared with before treatment. Additionally, serum levels of IL-1β and IL-6 showed a diminished recovery compared with controls. CONCLUSIONS: Our findings suggest immunological recovery in patients with pulmonary TB after intensive phase treatment. Therefore, serum cytokine levels are considered potential host biomarkers for monitoring the response of treatment for pulmonary TB. SAGE Publications 2018-05-13 2018-09 /pmc/articles/PMC6136029/ /pubmed/29756540 http://dx.doi.org/10.1177/0300060518773258 Text en © The Author(s) 2018 http://creativecommons.org/licenses/by-nc/4.0/ Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Clinical Research Reports Luo, Xuejiao Wu, Furong Ma, Jun Xiao, Heping Cui, Haiyan Immunological recovery in patients with pulmonary tuberculosis after intensive phase treatment |
title | Immunological recovery in patients with pulmonary tuberculosis after
intensive phase treatment |
title_full | Immunological recovery in patients with pulmonary tuberculosis after
intensive phase treatment |
title_fullStr | Immunological recovery in patients with pulmonary tuberculosis after
intensive phase treatment |
title_full_unstemmed | Immunological recovery in patients with pulmonary tuberculosis after
intensive phase treatment |
title_short | Immunological recovery in patients with pulmonary tuberculosis after
intensive phase treatment |
title_sort | immunological recovery in patients with pulmonary tuberculosis after
intensive phase treatment |
topic | Clinical Research Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6136029/ https://www.ncbi.nlm.nih.gov/pubmed/29756540 http://dx.doi.org/10.1177/0300060518773258 |
work_keys_str_mv | AT luoxuejiao immunologicalrecoveryinpatientswithpulmonarytuberculosisafterintensivephasetreatment AT wufurong immunologicalrecoveryinpatientswithpulmonarytuberculosisafterintensivephasetreatment AT majun immunologicalrecoveryinpatientswithpulmonarytuberculosisafterintensivephasetreatment AT xiaoheping immunologicalrecoveryinpatientswithpulmonarytuberculosisafterintensivephasetreatment AT cuihaiyan immunologicalrecoveryinpatientswithpulmonarytuberculosisafterintensivephasetreatment |